About ▼ Careers Internship MedBlog Contact us

LOGIN REGISTER

Advertisement

Medindia » Health Press Releases A-Z

NexBio Initiates Phase II Trial of DAS181 (Fludase(R)*) for Treatment of Influenza, Including Pandemic Influenza A(H1N1)

Advertisement

Contact:

David Wurtman, M.D., M.B.A.
VP, Corporate Development
10665 Sorrento Valley Road
San Diego, CA 92121
Phone: (858) 452-2631
[email protected]

Sponsored Post and Backlink Submission

Latest Press Release on Respiratory Disease News

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of Filipino participants MANILA , Australia , March 25, 2024 /PRNew...

Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB

AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures CANBERRA, Australia , March 24, 2024 /PRNewswire/ -- The Australian Government, through the Partnerships fo...

CGTN: China advances battle against tuberculosis

BEIJING , March 24, 2024 /PRNewswire/ -- World Tuberculosis (TB) Day, which falls on March 24 every year, is designed to build public awareness that TB today remains a global pu...

Joint Statement from the Chief Public Health Officer of the Public Health Agency of Canada and the Chief Medical Officer of Public Health of Indigenous Services Canada on World Tuberculosis Day 2024

OTTAWA, ON , March 24, 2024 /CNW/ - Sunday, March 24 marks World Tuberculosis (TB) Day. This is a day to raise awareness about the health, social, and economic impacts of this p...

CosmosID Announces Collaboration with Resilient Biotics for Advanced Microbiome Exploration of the Respiratory Tract

DURHAM, N.C. , March 21, 2024 /PRNewswire/ -- CosmosID, a renowned microbiome analytics company, is thrilled to announce a groundbreaking collaboration with Resilient Biotics, a l...

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use Ok, Got it. Close